The effect of low doses of mirtazapine and quetiapine on sleep and daytime functioning.

Phase 4

• Conditions: insomnie; sleep disorder; sleeplessness

• Registration Number: NL-OMON40193
• Lead Sponsor: GGZ Drenthe (Assen)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 25

Inclusion Criteria

Non-smoking, male, between the ages of 18 and 35 years.

Exclusion Criteria

Past or present sleeping disorder and/or psychiatric disorder, a family history of sleeping disorder and/or psychiatric disorder, liver disease, cardiovascular disease, alcohol- or substance dependence, medication use (including psychotropic medication), known intolerance for mirtazapine or quetiapine, a BMI of or below 18.5 or of or above 30.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Sleep polysomnography and subjective sleep. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Daytime sleepiness and daytime cognitive functioning.</p><br>